🔥Telegram İfşa

Welcome to UNSW and UNSW Medicine & Health Cheryl!

UNSW is committing $700,000 to a Health Tech Entrepreneurship Program that will support South Western Sydney-based researchers and entrepreneurs to start and scale their ventures. The program will be an expansion of UNSWFounders based in Liverpool Innovation Precinct: unsw.edu.au/newsroom/news/…

UNSW and Cancer Council NSW (@ccnewsouthwales ) have joined forces to establish an Australian-first research centre for cancer survivors, which will focus on improving care and wellbeing for the increasing number of people living with and beyond cancer. unsw.edu.au/newsroom/news/…

How does Semaglutide protect the kidneys? Is it weight loss? Glycemic control? According to ⁦Swapnil Hiremath @hswapnil.medsky.social⁩, who cares! Plus a reduction in the all important "Hit-by-bus-outcome by ⁦Joshua Waitzman, MD PhD⁩

#ADASciSessions look out for FLOW with updates today ! Vlado Perkovic Steno Diabetes Center Copenhagen

see the SGLT2i and semaglutide interaction in FLOW nature.com/articles/s4159… consistent effect regarding mortality, MACE and slope in GFR Vlado Perkovic Steno Diabetes Center Copenhagen

#FLOW #SGLT2i Subgroup #SimPub #ADA2024 in Nature Medicine: #GLP1RA semaglutide by background #SGLT2i in #T2D & #CKD After hint of interaction for PEP, convincingly consistent protection against mortality, MACE, eGFR decline, irrespective of #SGLT2i use nature.com/articles/s4159…

Check the recorded session! What is like to be a Principal Investigator with Vlado Perkovic #Clinical #Trials #CKD #GLP #Flow #Semaglutide #Prevention x.com/isnkidneycare/… #ThisIsISN Int Society of Nephrology

Today: The New England Journal of Nephrology Deutsche Gesellschaft für Nephrologie (DGfN) e.V. @oegnephro SFNDT Contributions from Will Herrington Katherine Tuttle Vlado Perkovic @RichardHaynes3 and many others...

1/3 🚧 🔨Construction Update! 🚧 🔨 We’ve reached a major milestone at the UNSW Health Translation Hub, with the successful installation of the project's pedestrian footbridge officially connecting our Kensington campus to the Randwick Health Campus!

Excited to dive into GlomCon Hawaii's session on clinical trial endpoints with Prof Vlado Perkovic! While there's still less focus on 'feels and functions,' we're making progress. Let's reshape kidney disease research for better patient outcomes! #GlomConHawaii #ClinicalTrials

New in NEJM Evidence! Original Article by Jeffrey Ha @jeffreyha.bsky.social et al.: Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease eviden.cc/3z2CLzM Sunil Badve Min Jun Swapnil Hiremath @hswapnil.medsky.social Daniel Coyne Suetonia Palmer David C Wheeler Vlado Perkovic The George Institute for Global Health UNSW Medicine & Health

Chronic kidney disease (CKD) and cardiovascular disease (CVD) are closely linked, with CKD emerging as a major CVD risk factor. Early detection and novel therapies targeting both conditions could transform patient outcomes Sradha Kotwal Vlado Perkovic ahajournals.org/doi/full/10.11…

overFLOWing evidence for semaglutide in CKD: here come the heart failure data 😎 Thank you Richard Pratley MD Katherine Tuttle Peter Rossing Vlado Perkovic and the other FLOW investigators! sciencedirect.com/science/articl…

Original Article: Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy (APPLAUSE-IgAN) nej.md/3UmrOkh Editorial: Waystations in Progress — Burgeoning Treatment Options for IgA Nephropathy nej.md/4fdz9dV #KidneyWk | American Society of Nephrology

1/2 UNSW’s Kirby Institute has received a record $25.9 million donation from the Swire Group to support vital cervical cancer screening and treatment services for more than 130,000 women across the Pacific.

Wow! 🚨 The #ERA2025 Late-Breaking Trials delivered again: ✅ Promising data in IgA nephropathy ✅ SGLT2 inhibitors reaffirm their place ✅ MR antagonists show strength We’re not just managing CKD—we’re reshaping it. #Nephrology #KidneyHealth Vlado Perkovic

New episode of #KidneyCompass incoming! Discussing the late breaking #VISIONARY trial of #sibeprenlimab in #IgAN, changing standards of care, & new trial designs with Shikha Wadhwani & Vlado Perkovic The FOMO in Sydney is real... wish I was at #ERA25!! Patrick Campbell

Had the BEST time discussing #IgAN and the new VISIONARY data with the amazing Vlado Perkovic ! Podcast episode out soon—and Brendon Neuen even joined us from across the pond! #ERA2025

Sibeprenlimab Halves uPCR in IgA Nephropathy (IgAN) Trial from Vlado Perkovic Medscape #ERA25 🇦🇹 #Nephpearls medscape.com/viewarticle/si…